Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate‐specific antigen testing: 15‐year outcome

• Published in: BJU international Vol. 95; no. 6; pp. 751 - 756
• Main Authors: Ward, John F., Slezak, Jeffrey M., Blute, Michael L., Bergstralh, Erik J., Zincke, Horst
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01.04.2005; Blackwell
• Subjects: Aged; Antineoplastic Agents, Hormonal - therapeutic use; Biological and medical sciences; Disease-Free Survival; Gynecology. Andrology. Obstetrics; Humans; Male; Male genital diseases; Medical sciences; Middle Aged; Neoplasm Staging - methods; Nephrology. Urinary tract diseases; Prostate-Specific Antigen - blood; prostatectomy; Prostatectomy - methods; prostatic neoplasm; Prostatic Neoplasms - blood; Prostatic Neoplasms - pathology; Prostatic Neoplasms - surgery; Retrospective Studies; staging; Treatment Outcome; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Histological grading; Human; Nephrology; Urinary system disease; Prognosis; Prostate disease; prostatic neoplasm; Tumoral marker; Malignant tumor; treatment outcome; Urology; Prostate specific antigen; Anatomic pathology; Cancerology; Histopathology; Treatment; Surgery; Prostatectomy; Advanced stage; Male genital diseases; Prostate cancer; staging

In the first paper in this section, authors from the Mayo Clinic describe their experience and 15‐year outcomes in the controversial subject of radical prostatectomy in patients with clinical T3 prostate cancer. The findings were interesting in many respects, but the authors concluded that radical p...